Tela Bio Inc

NASDAQ TELA

Data sourced from

and

Download Data

Tela Bio Inc Gross Profit Margin for the year ending December 31, 2023: 68.62%

Tela Bio Inc Gross Profit Margin is 68.62% for the year ending December 31, 2023, a 5.10% change year over year. Gross Profit Margin represents the percentage of revenue that represents gross profit, indicating the efficiency of a company's production and pricing.

Tela Bio Inc Gross Profit Margin for the year ending December 31, 2022 was 65.30%, a 2.26% change year over year.
Tela Bio Inc Gross Profit Margin for the year ending December 31, 2021 was 63.85%, a 3.52% change year over year.
Tela Bio Inc Gross Profit Margin for the year ending December 31, 2020 was 61.68%, a 2.75% change year over year.
Tela Bio Inc Gross Profit Margin for the year ending December 31, 2019 was 60.03%, a 68.82% change year over year.

NASDAQ: TELA

Tela Bio Inc

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway, Malvern, PA, United States, 19355
Employees	227
Sector	Healthcare
Industry	Medical devices

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends